<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: <z:chebi fb="37" ids="16236,44730">Ethanol</z:chebi> and <z:chebi fb="111" ids="27732">caffeine</z:chebi> are 2 common psychoactive dietary components </plain></SENT>
<SENT sid="1" pm="."><plain>We have recently shown that low-dose <z:chebi fb="37" ids="16236,44730">ethanol</z:chebi> plus <z:chebi fb="111" ids="27732">caffeine</z:chebi> results in a 70% to 80% reduction of <z:mpath ids='MPATH_124'>infarct</z:mpath> volume after reversible common carotid/middle cerebral artery (CCA/<z:chebi fb="70" ids="34342">MCA</z:chebi>) occlusion in rats </plain></SENT>
<SENT sid="2" pm="."><plain>The combination (caffeinol) was effective after either oral pretreatment or intravenous administration starting up to 2 hours after <z:hpo ids='HP_0001297'>stroke</z:hpo> <z:hpo ids='HP_0003674'>onset</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="37" ids="16236,44730">Ethanol</z:chebi> alone aggravated ischemic damage, while <z:chebi fb="111" ids="27732">caffeine</z:chebi> alone was without effect </plain></SENT>
<SENT sid="4" pm="."><plain>Daily caffeinol for 2 weeks before <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> eliminated the neuroprotection seen with <z:hpo ids='HP_0011009'>acute</z:hpo> treatment (tolerance) </plain></SENT>
<SENT sid="5" pm="."><plain>The purpose of our present study was to further characterize the properties of caffeinol as a possible treatment for <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>METHODS: The transient CCA/<z:chebi fb="70" ids="34342">MCA</z:chebi> occlusion model was used in <z:hpo ids='HP_0000001'>all</z:hpo> experiments </plain></SENT>
<SENT sid="7" pm="."><plain>Five sets of experiments were conducted (1) to test the effectiveness of various doses of <z:chebi fb="37" ids="16236,44730">ethanol</z:chebi> (0.2 to 0.65 g/kg) and <z:chebi fb="111" ids="27732">caffeine</z:chebi> (3 to 10 mg/kg) in the caffeinol mixture; (2) to test whether the neuroprotective dose of caffeinol can improve behavioral dysfunction; (3) to test whether <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:chebi fb="37" ids="16236,44730">ethanol</z:chebi> or <z:chebi fb="111" ids="27732">caffeine</z:chebi> before <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> will affect efficacy of caffeinol treatment; (4) to test whether the protective effect of caffeinol can be improved by pairing it with 35 degrees C <z:hpo ids='HP_0002045'>hypothermia</z:hpo>; and (5) to test whether caffeinol affects frequency of <z:mp ids='MP_0001914'>hemorrhage</z:mp> after administration of recombinant tissue plasminogen activator (rtPA) in ischemic animals </plain></SENT>
<SENT sid="8" pm="."><plain>RESULTS: Doses as low as 0.2 g/kg of <z:chebi fb="37" ids="16236,44730">ethanol</z:chebi> and 6 mg/kg of <z:chebi fb="111" ids="27732">caffeine</z:chebi> in the caffeinol were effective in reducing cortical <z:mpath ids='MPATH_124'>infarct</z:mpath> volume and behavioral dysfunction after transient CCA/<z:chebi fb="70" ids="34342">MCA</z:chebi> occlusion </plain></SENT>
<SENT sid="9" pm="."><plain>Daily exposure to <z:chebi fb="37" ids="16236,44730">ethanol</z:chebi> but not <z:chebi fb="111" ids="27732">caffeine</z:chebi> before CCA/<z:chebi fb="70" ids="34342">MCA</z:chebi> occlusion eliminated the therapeutic efficacy of <z:hpo ids='HP_0011009'>acute</z:hpo> caffeinol treatment, similar to the tolerance observed after <z:hpo ids='HP_0011010'>chronic</z:hpo> exposure to caffeinol </plain></SENT>
<SENT sid="10" pm="."><plain>The therapeutic effect of caffeinol could be further improved by pairing it with mild intraischemic <z:hpo ids='HP_0002045'>hypothermia</z:hpo>, and caffeinol did not increase hemorrhagic infarction when given in combination with rtPA </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: Low doses of caffeinol, equivalent to no more than 2 to 3 cups of strong coffee and 1 cocktail, are consistently and highly neuroprotective, are well tolerated, can be added to other therapies to increase the effect of each, and do not interfere with or complicate rtPA therapy </plain></SENT>
<SENT sid="12" pm="."><plain>Caffeinol is an appropriate candidate for clinical trial in <z:hpo ids='HP_0001297'>stroke</z:hpo> patients, although it may be less effective in patients with regular alcohol intake </plain></SENT>
</text></document>